Author:
Xiang Lei,Rao Qi,He Bin,Guo Xiao-hong,Xu Yun-dan,Luo Bao-ping,Zhao Gang,Wu Feng-hua
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Knudsen KE, Diehl JA, Haiman CA, et al. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene, 2006,25(11):1620–1628
2. Wang Y, Dean JL, Millar EKA, et al. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res, 2008,68(14):5628–5638
3. Augello MA, Berman-Booty LD, Carr3rd R, et al. Consequence of the tumor-associated conversion to cyclin D1b. EMBO Mol Med, 2015,7(5):628–647
4. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res, 2003,63(21):7056–7061
5. Kim CJ, Tambe Y, Mukaisho K, et al. Female-specific rectal carcinogenesis in cyclin D1b transgenic mice. Carcinogenesis, 2014,35(1):227–236